$-35.69
(Market cap
$63,631 Mln
Revenue (TTM)
$8,446 Mln
P/E Ratio
38.9
P/B Ratio
7.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.2 %
-
ROCE
20 %
-
Industry P/E
--
-
EV/EBITDA
34.2
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$39.6
-
Face value
--
-
Shares outstanding
62,187,771
10 Years Aggregate
CFO
$-2,281.02 Mln
EBITDA
$-2,075.38 Mln
Net Profit
$-2,407.69 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
argenx SE - ADR
| 21.7 | 15.1 | 24.7 | 44.5 | 26.4 | 24.9 | -- |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P 100
| 10.3 | 5.0 | 2.3 | 18.8 | 22.8 | 13.0 | 14.8 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
argenx SE - ADR
| 36.7 | 61.3 | 0.2 | 8.2 | 19.1 | 83.2 | 67.1 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
argenx SE - ADR
|
1,023.2 | 63,631.2 | 8,446.3 | 2,595.8 | 21.8 | 33 | 38.9 | 7.9 |
| 13.5 | 850.9 | 0.0 | -175.9 | -- | -106.8 | -- | 5.7 | |
| 33.2 | 20,720.0 | 4,131.1 | 788.1 | 21.5 | 13.4 | 26.2 | 3.5 | |
| 12.4 | 2,151.8 | 549.1 | 17.9 | -6.3 | 1.4 | 123.8 | 1.7 | |
| 17.4 | 2,261.9 | 65.4 | -94.4 | -108.2 | -16.1 | -- | 4.1 | |
| 11.7 | 828.1 | 366.5 | 9.3 | 8.3 | 3.4 | 83.6 | 3.1 | |
| 3.6 | 654.8 | 4.1 | -187.9 | -4,613.1 | -233.9 | -- | 0.3 | |
| 13.4 | 834.1 | 0.6 | -59.9 | -9,892.6 | -118.9 | -- | 21.8 | |
| 6.4 | 609.7 | 143.5 | -158.2 | -80.2 | -168.9 | -- | 6.6 | |
| 26.1 | 2,927.9 | 449.6 | -188.2 | -41.1 | -28.5 | -- | 5.0 |
Shareholding Pattern
View DetailsAbout argenx SE - ADR
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and... immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands. Read more
-
CEO & Executive Director
Mr. Timothy Van Hauwermeiren EMBA, M.B.A., M.Sc.
-
CEO & Executive Director
Mr. Timothy Van Hauwermeiren EMBA, M.Sc.
-
Headquarters
Amsterdam
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for argenx SE - ADR
What is the current share price of argenx SE - ADR Today?
The share price of argenx SE - ADR is $1,023.21 (NASDAQ) as of 28-Aug-2026 16:00 EDT. argenx SE - ADR has given a return of 26.37% in the last 3 years.
What is the current PB & PE ratio of argenx SE - ADR?
The P/E ratio of argenx SE - ADR is 38.95 times as on 28-Aug-2026.
The P/B ratio of argenx SE - ADR is 7.87 times as on 28-Aug-2026, a 63 premium to its peers’ median range of 4.82 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
43.09 |
7.60 |
2024 |
52.38 |
7.94 |
2023 |
-75.01 |
5.40 |
2022 |
-29.53 |
7.45 |
2021 |
-44.19 |
7.12 |
What is the 52 Week High and Low of argenx SE - ADR?
The 52-week high and low of argenx SE - ADR are Rs 1,061.57 and Rs 661.85 as of 30-Aug-2026.
What is the market cap of argenx SE - ADR?
argenx SE - ADR has a market capitalisation of $ 63,631 Mln as on 28-Aug-2026. As per SEBI classification, it is a Large Cap company.
Should I invest in argenx SE - ADR?
Before investing in argenx SE - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.